Welcome to our dedicated page for Ibex SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the story behind IBEX’s rapid expansion into AI-powered contact centers? Start with the disclosures investors trust most. Our SEC Filings hub untangles every IBEX document—whether you need the IBEX annual report 10-K simplified to gauge client concentration risk or an IBEX quarterly earnings report 10-Q filing to track segment margins.
Finding those details across hundreds of pages is tedious. Stock Titan applies AI that highlights wage inflation in nearshore sites, flags capital spending on the Wave iX platform, and provides instant alerts for IBEX insider trading Form 4 transactions. The result: understanding IBEX SEC documents with AI becomes a five-minute task.
Use the menu to jump straight to what professionals ask for most:
- Real-time Form 4 feed – follow IBEX executive stock transactions Form 4 and get context around each trade.
- 8-K event briefs – see IBEX 8-K material events explained minutes after they hit EDGAR, from new client wins to leadership changes.
- DEF 14A proxy tools – decode IBEX proxy statement executive compensation without spreadsheet gymnastics.
- Earnings pack – one click reveals our IBEX earnings report filing analysis and historical KPIs.
Every filing—10-K, 10-Q, 8-K, S-8, SC 13G, or the next IBEX Form 4 insider transactions real-time—arrives here within seconds of EDGAR publication and is paired with plain-English summaries. Monitor contract renewal clauses, compare headcount by region, or assess AI capital spend—all without sifting through dense legal text. Complex disclosures, made clear.
Robert Thomas Dechant, Chief Executive Officer and a director of IBEX Ltd (IBEX), had 14,524 performance-based stock units (PSUs) convert to common shares on September 30, 2025 after certification of performance goals for the period ending June 30, 2025. To satisfy tax-withholding obligations related to that vesting, 6,711 shares were sold in multiple trades on October 2, 2025 at a weighted average price of $39.5817 per share. Following these transactions, the reporting person beneficially owns 199,812 common shares.
Form 144 notice for IBEX Ltd (IBEX) reports a proposed sale of 2,295 common shares with an aggregate market value of $93,475.69. The sale is listed on NASDAQ and the approximate sale date is 09/19/2025. The securities were acquired on 09/18/2025 by vesting of a grant from the issuer, with 7,500 shares shown as acquired on that date. A prior sale by the same person, Taylor C Greenwald, recorded 438 shares sold on 08/26/2025 for $12,757.51. Broker listed: Global Shares Financial Services Inc.
IBEX Ltd (IBEX) reporting person Taylor C. Greenwald, Chief Financial Officer, sold 2,295 common shares on 09/19/2025 at $40.7302 per share. The Form 4 shows the sale was required to cover tax withholding for restricted stock units that vested and is not described as a discretionary trade. After the transaction the reporting person beneficially owned 33,561 shares, held directly. The filing was signed by an attorney-in-fact on 09/23/2025. No options, derivative transactions, or other compensatory arrangements are disclosed on this Form 4.
Julie K. Casteel, Chief Sales/Marketing Officer of IBEX Ltd (IBEX), reported a sale of common shares. On 09/16/2025 she disposed of 5,000 common shares at a price of $39.0002 per share, leaving her with 25,895 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
IBEX Ltd filed a Form 144 notice disclosing a proposed sale of 5,000 shares of its common stock by an insider. The filing names Charles Schwab as the broker and lists an approximate sale date of 09/16/2025 on Nasdaq. The shares were acquired as stock grants on 12/31/2018 and paid via equity compensation. The filing also reports a recent sale of 295 shares on 07/01/2025 for $8,592. The filer affirms no undisclosed material adverse information.
IBEX Ltd Form 4 summary: The filing by Bruce Neil Dawson reports transactions in IBEX Ltd (IBEX) on 09/16/2025. The reporting person executed an acquisition of 8,114 common shares (code M) at a reported price of $19.00, and two sales of common shares the same date: 8,114 shares sold at a weighted average price of $38.14 and 765 shares sold at a reported price of $38.2903. Following the reported transactions, the filing shows beneficial ownership levels of 13,371, 5,257, and 4,492 shares on the respective lines. The seller notes the sales were executed in multiple trades at prices ranging from $38.2901 to $38.35 and offers to provide further breakdowns on request. The form is signed by an attorney-in-fact, Lisa Lenstrohm, dated 09/17/2025.
IBEX Ltd insider Robert Thomas Dechant reported same-day non-derivative transactions on 09/16/2025. He acquired 45,027 common shares at $19.00, bringing his beneficial ownership to 237,026 shares (direct), and sold 45,027 common shares at $38.89, leaving 191,999 shares (direct) after the transactions. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Form 4 shows that Christina Trofimuk-O'Connor, Chief Legal Officer of IBEX Ltd (IBEX), reported a sale of 844 common shares on 09/16/2025 at a price of $38.50 per share. After the reported transaction she beneficially owns 11,727 shares, held directly. The filing was made as a single reporting person and signed by an attorney-in-fact on 09/17/2025.
IBEX Ltd (Form 144): A proposed sale of 8,114 common shares is notified for sale on 09/16/2025 through Global Shares Financial Services Inc. The filing reports an aggregate market value of $309,467.96 and lists 13,315,077 shares outstanding for the issuer. The shares were originally acquired on 08/07/2020 as a grant from the issuer. The filer also reported a recent sale of 350 shares on 08/26/2025 generating $10,194.36 in gross proceeds. The notice includes the required representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Form 144 notice for IBEX Ltd shows a proposed sale of 45,027 common shares by the person named, with an aggregate market value of $1,751,100.03 and an approximate sale date of 09/16/2025 on NASDAQ. The shares were acquired as a grant on 08/07/2020. The filing also discloses a prior sale by the same person of 1,634 shares on 08/26/2025 for gross proceeds of $47,593.10. The filer certifies they have no undisclosed material adverse information about the issuer and includes the standard Rule 144 attestation language.
FAQ
What is the current stock price of Ibex (IBEX)?
What is the market cap of Ibex (IBEX)?
